Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 20192028
- Published Date: 2020-10-18
- Report ID: 3627
- Pages: 309
-
Format:
The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028.
Beta-lactam and beta-lactamase inhibitors is a most important type of antibacterial agent used for fighting bacterial infections. In addition, these are used to kill or prevent the growth of microorganisms. Based on the molecular structure, beta-lactam and beta-lactamase inhibitors are drug classified into penicillin, cephalosporin, carbapenem, monobactam, and combination.
There is an increase in the demand for beta-lactam and beta-lactamase inhibitors, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The global beta-lactam and beta-lactamase inhibitors market is segmented based on drug class, disease, route of administration, and region. Based on the drug class, the market is classified into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. Depending on the disease segment, the market is divided into urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, blood stream infection, and other diseases. Nosocomial pneumonia segment is further divided into hospital acquired pneumonia, ventilator associated pneumonia, and other nosocomial pneumonia. Based on route of administration, the market is classified into oral, intravenous, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Drug Class
o Penicillin
o Cephalosporin
o Carbapenem
o Monobactam
o Combination
Penicillin/Beta Lactamase Inhibitors
Cephalosporins/Beta Lactamase Inhibitors
Carbapenems/Beta Lactamase Inhibitors
By Disease
o Urinary Tract Infection (excluding cUTI)
o Respiratory Infection
o Skin Infection
o Complicated Urinary Tract Infection (cUTI)
o Complicated Intra-Abdominal Infections (cIAI)
o Nosocomial Pneumonia
Hospital Acquired Pneumonia
Ventilator Associated Pneumonia
Other Nosocomial Pneumonia
o Blood Stream Infection
o Other Diseases
By Route of Administration
o Oral
o Intravenous
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
Spain
Italy
UK
Rest of Europe
o Asia-Pacific
Japan
India
China
South Korea
Thailand
Taiwan
Vietnam
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
The other players in the value chain (profiles not included in the report)
Hikma Pharmaceuticals
Melinta Therapeutics
Eli Lilly and Company
Shionogi, Inc.
AstraZeneca plc
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Winning Strategies
3.3.1. Top Player Positioning, 2018
3.4. PorterS Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections
3.5.2. Restraints
3.5.2.1. Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies
3.5.3. Opportunity
3.5.3.1. Discovery of Advanced Prospect Molecules And Novel Combination Therapies To Treat Antibiotic-Resistant Microbial Infections
3.6. Antimicrobial Resistance And Countermeasure Trends
3.6.1. Countermeasure Trends
Chapter 4: Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Penicillin
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Cephalosporin
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Carbapenem
4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Monobactam
4.5.1. Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Combination
4.6.1. Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type
4.6.2.1. Penicillin/Beta Lactamase Inhibitors
4.6.2.1.1. Market Size And Forecast
4.6.2.2. Cephalosporins/Beta Lactamase Inhibitors
4.6.2.2.1. Market Size And Forecast
4.6.2.3. Carbapenems/Beta Lactamase Inhibitors
4.6.2.3.1. Market Size And Forecast
4.6.3. Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country
Chapter 5: Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Urinary Tract Infection (Excluding Cuti)
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Respiratory Infection
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Skin Infection
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
5.5. Complicated Urinary Tract Infection (Cuti)
5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country
5.6. Complicated Intra-Abdominal Infections (Ciai)
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country
5.7. Nosocomial Pneumonia
5.7.1. Market Size And Forecast, By Type
5.7.1.1. Hospital Acquired Pneumonia
5.7.1.1.1. Market Size And Forecast
5.7.1.2. Ventilator Associated Pneumonia
5.7.1.2.1. Market Size And Forecast
5.7.1.3. Other Nosocomial Pneumonia
5.7.1.3.1. Market Size And Forecast
5.7.2. Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country
5.8. Blood Stream Infection
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country
5.9. Other Diseases
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Analysis, By Country
Chapter 6: Beta-Lactam And Beta Lactamase Inhibitors Market, By Route of Administration
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Oral
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Intravenous
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country
6.4. Others
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country
Chapter 7: Beta-Lactam And Beta-Lactamase Inhibitors Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.2.2.1. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.2. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.3. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.4. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.5. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.6. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.7. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.8. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.9. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.3. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.2.4. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.2.5. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.3. Europe
7.3.1. Key Market Trends And Opportunities
7.3.2. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.3.2.1. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.2. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.3. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.4. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.5. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.6. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.7. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.8. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.9. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.10. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.11. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.12. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.13. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.14. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.15. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.16. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.17. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.18. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.3. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.3.4. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.3.5. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.4. Asia-Pacific
7.4.1. Key Market Trends And Opportunities
7.4.2. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.4.2.1. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.2. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.3. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.4. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.5. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.6. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.7. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.8. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.9. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.10. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.11. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.12. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.13. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.14. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.15. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.16. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.17. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.18. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.19. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.20. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.21. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.22. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.23. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.24. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.25. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.26. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.27. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.3. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.4.4. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.4.5. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
7.5. Lamea
7.5.1. Key Market Trends And Opportunities
7.5.2. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country
7.5.2.1. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.2. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.3. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.4. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.5. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.6. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.7. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.8. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.9. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.10. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.11. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.12. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.3. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.5.4. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.5.5. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration
Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Allergan Plc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. F. Hoffmann-La Roche Ltd.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Glaxosmithkline Plc
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Merck & Co. Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Mylan N.V.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Novartis International Ag (Sandoz)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Pfizer Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
